Document is current
Any future updates will be listed below
-
Authors
Ko, Gary
Hallet, Julie
Jerzak, Katarzyna J.
Chan, Wing
Coburn, Natalie
Barabash, Victoria
Wright, Frances C.
Look Hong, Nicole J.
-
Funding
Funding for this research was provided by:
Institute of Health Services and Policy Research (Understanding and predicting long-term outcomes of)
- License Information
-
More Information
Article History
Received: 1 July 2022
Accepted: 22 September 2022
First Online: 18 October 2022
Disclosures
: Katarzyna J. Jerzak reports personal honoraria and consulting or advisory fees from Amgen, AstraZeneca, Apobiologix, Eli Lilly, Eisai, Exact Sciences, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc., Pfizer, F. Hoffmann-La Roche Ltd, Novartis, Seagen, and Viatris, as well as institutional research funding from Eli Lilly, AstraZeneca and Seagen. She also holds a patent regarding the use of dronedarone and related derivatives as anticancer agents (patent publication #WO/2017/106974). Gary Ko, Julie Hallet, Wing Chan, Natalie Coburn, Victoria Barabash, Frances C. Wright, and Nicole J. Look Hong have no disclosures to declare.
